ISDA

Entry Detail

PDB ID:

3UW5

Keywords:

Apoptosis Inhibitor

Title:

Crystal structure of the BIR domain of MLIAP bound to GDC0152

Biological Source:

Source Organism:

Homo sapiens,

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2011-11-30

Release Date:

2012-02-22

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.71 Å

R-Value Free:

0.16

R-Value Work:

0.15

R-Value Observed:

0.15

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Baculoviral IAP repeat-containing protein 7, Baculoviral IAP repeat-containing protein 4
Mutations:S150G
Chain IDs:A, B
Chain Length:116
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q96CA5 Pfam ID:PF00653

Polymer Type:polypeptide(L)
Description:GDC-0152
Chain IDs:C (auth: Z), D (auth: Y)
Chain Length:4
Number of Molecules:2
Biological Source:

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
MAA	C	ALA	N-METHYL-L-ALANINE

Ligand Molecules

SO4

Peptide-like Molecules

PRD_001020

Primary Citation

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152).

Flygare, J.A, Beresini, M, Budha, N, Chan, H, Chan, I.T, Cheeti, S, Cohen, F, Deshayes, K, Doerner, K, Eckhardt, S.G, Elliott, L.O, Feng, B, Franklin, M.C, Reisner, S.F, Gazzard, L, Halladay, J, Hymowitz, S.G, La, H, Lorusso, P, Maurer, B, Murray, L, Plise, E, Quan, C, Stephan, J.P, Young, S.G, Tom, J, Tsui, V, Um, J, Varfolomeev, E, Vucic, D, Wagner, A.J, Wallweber, H.J, Wang, L, Ware, J, Wen, Z, Wong, H, Wong, J.M, Wong, M, Wong, S, Yu, R, Zobel, K, Fairbrother, W.J.Show

J.Med.Chem. 55 4101 4113 (2012)

PMID: 22413863 DOI: 10.1021/jm300060k

Abstact

A series of compounds were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac. Compound 1 (GDC-0152) has the best profile of these compounds; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K(i) values of 28, 14, 17, and 43 nM, respectively. These compounds promote degradation of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells. Compound 1 inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model. Compound 1 was advanced to human clinical trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested. Mean plasma clearance in humans was 9 ± 3 mL/min/kg, and the volume of distribution was 0.6 ± 0.2 L/kg.

Legend

Protein

Chemical

Disease

Primary Citation of related structures